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Abstract
Nisin A is the most extensively studied lantibiotic and has been used as a preservative by the food industry since 1953. This
34 amino acid peptide contains three dehydrated amino acids and five thioether rings. These rings, resulting from one
lanthionine and four methyllanthionine bridges, confer the peptide with its unique structure. Nisin A has two mechanisms
of action, with the N-terminal domain of the peptide inhibiting cell wall synthesis through lipid II binding and the C-terminal
domain responsible for pore-formation. The focus of this study is the three amino acid ‘hinge’ region (N 20, M 21 and K 22)
which separates these two domains and allows for conformational flexibility. As all lantibiotics are gene encoded, novel
variants can be generated through manipulation of the corresponding gene. A number of derivatives in which the hinge
region was altered have previously been shown to possess enhanced antimicrobial activity. Here we take this approach
further by employing simultaneous, indiscriminate site-saturation mutagenesis of all three hinge residues to create a novel
bank of nisin derivative producers. Screening of this bank revealed that producers of peptides with hinge regions consisting
of AAK, NAI and SLS displayed enhanced bioactivity against a variety of targets. These and other results suggested a
preference for small, chiral amino acids within the hinge region, leading to the design and creation of producers of peptides
with hinges consisting of AAA and SAA. These producers, and the corresponding peptides, exhibited enhanced bioactivity
against Lactococcus lactis HP, Streptococcus agalactiae ATCC 13813, Mycobacterium smegmatis MC2155 and Staphylococcus
aureus RF122 and thus represent the first example of nisin derivatives that possess enhanced activity as a consequence of
rational design.
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Introduction
Bacteriocins are small, bacterially produced, ribosomally
synthesized peptides that are active against other bacteria and
against which the producer has a specific immunity mechanism
[1,2]. The bacteriocins can be subdivided on the basis of their
structure with Class 1 consisting of peptides that have undergone
post-translational modification [3]. Of these, the lantibiotics have
been the focus of particular attention [4,5]. The name of these
bacteriocins reflects their structure; ‘Lanthionine-containing
antibiotics’, where lanthionines/b-methyllanthionines are un-
usual residues that are formed between cysteines and neighbouring
dehydrated serines (dehydroalanines) or threonines (dehydrobu-
tyrines), respectively [5].
The lantibiotic Nisin A (Fig. 1) has been used a commercial food
additive since 1953 and has been approved for use in food by the
FAO, WHO, EU and the USFDA [1,6]. Unsurprisingly, Nisin A
is by far the most extensively studied lantibiotic [1,6,7]. In
addition, the gene encoded nature of nisin, and indeed other
lantibiotics, can be exploited through engineering to even further
enhance its activity and/or investigate structure-function relation-
ships. Such engineering can be carried out in vivo (manipulation of
the producer or heterologous expression of the genes in another
host) or in vitro (using purified components of the biosynthetic
machinery) [8–11].
The in vivo engineering of nisin through the replacement of
specific amino acids commenced in 1992 [12] and a number of
derivatives were identified that have been of considerable value
with respect to revealing the fundamentals of nisin biology [13,14].
More recently, derivatives have been identified with academic and
potential commercial value that display enhanced activity against
pathogenic bacteria [8,15–19]. The majority of these enhanced
derivatives differ with respect to the amino acids found in the 3
amino acid ‘hinge’ region of the peptide. This region is thought to
be key with respect to linking the two functional domains of the
nisin peptide and providing conformational flexibility between
these regions [20,21]. Nisin inhibits cell wall synthesis through the
formation of a complex with lipid II, an essential precursor of
peptidoglycan synthesis [22,23], with the N-terminus region being
responsible for this binding [24]. The hinge links this domain with
the C-terminal end of the peptide, which is responsible for a
second mechanism of antimicrobial activity, which involves
permeabilization of the cell membrane. The first indication that
mutagenesis of the hinge could bring about beneficial conse-
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quences was provided by Yuan and co-workers [18] who
established that two derivatives of nisin Z (N20K and M21K),
exhibited enhanced activity against Gram negative (Shigella,
Peudomonas and Salmonella), but not Gram positive, pathogens.
This was followed by the identification of hinge derivatives, such as
N20P, M21V, K22S and K22T [8], with enhanced activity
against Gram positive pathogens (Streptococcus agalactiae, Staphylococ-
cus aureus and Listeria monocytogenes). Further studies have empha-
sised the enhanced potency of one of these variants, nisin V
(M21V) [25], against a broad variety of drug-resistant pathogens
and have identified other hinge derivatives, such as that containing
the residues SVA, that exhibit enhanced activity in complex
matrices [17].
The hinge derivatives which have been studied to date have
resulted from strategies in which one or two of the hinge residues
have been manipulated. Here we go a step further through the
randomisation of all three hinge residues simultaneously. Screen-
ing of a bank of producers of such derivatives revealed a pattern
whereby many producers of derivatives containing small chiral
amino acids within the hinge displayed enhanced bioactivity. This
prompted the rational design of additional derivatives not
identified from the random bank, peptides containing AAA and
SAA hinges, which were particularly notable with respect to the
extent to which bioactivity was enhanced relative to the wild type
producer.
Experimental Procedures
Bacterial strains and growth conditions
All strains and plasmids used in this study are listed in Table 1.
Lactococcus lactis cultures were grown in M17 broth or agar (1.5%)
(Oxoid) supplemented with 0.5% glucose at 30uC. Escherichia coli
strains were grown in Luria-Bertani (LB) broth or agar with
continuous shaking at 37uC. Where necessary, chloramphenicol
was used at 10 mg/ml for L. lactis and E. coli. Staphylococcus aureus
RF122 was grown in Brain Heart Infusion (BHI) broth or agar
(Oxoid) at 37uC. Streptococcus agalactiae ATCC 13813 was grown in
Tryptic Soy Broth (TSB) (Merck) or TS agar supplemented with
Yeast Extract (YE) (Oxoid) at a concentration of 0.6% at 37uC.
Mycobacterium smegmatis MC2155 was grown on Middlebrook 7H9
broth (BD) or Middlebrook 7H10 agar (BD) supplemented with
0.05% tween 80 and 2% glycerol at 37uC.
Site-saturation mutagenesis of the nisin A ‘hinge’ region
The complete randomisation of the ‘hinge’ amino acids was
achieved by PCR using the template pDF05 (pCI372–nisA) and
primers NisAXXXHingeFor and NisAXXXHingeRev (Table 2).
The template DNA was extracted using a High Pure Plasmid
Isolation Kit (Roche) from dam+ E. coli Top10 (Invitrogen) to
ensure its methylation. PCR amplification was performed in 50 ml
volumes with 1 ng per 50 ml of template, 2 units of Phusion High
Fidelity DNA Polymerase (Finnzymes), approximately 0.5ng of
template, 1x HF buffer, 200 mM dNTPs and 0.5 mM of the
relevant oligonucleotides. Cycling conditions were as follows: 98uC
for 30 secs, 55uC for 15 secs, 72uC for 3.5 mins for 40 cycles
followed by final extension for 10 mins. Samples were PCR
cleaned using GeneJet PCR Purification Kit (Thermo Scientific)
followed by DpnI treatment (Stratagene) at 37uC for 3 hours.
2.5 ml of mutated pCI372-NisA was added to a vial of Top 10
Chemically Competent E. coli (Invitrogen). These transformants
were pooled, plasmids extracted using a High Pure Plasmid
Isolation Kit (Roche) and transformed into electro-competent. L.
lactis ssp. cremoris NZ9800nnisA and selected for on GM17 Cm10
agar within Q-Trays. Resultant colonies were picked and added to
GM17 within Genetix 96-well plates (Genetix X6011), incubated
overnight at 30uC before storage at –80uC in 44% glycerol
(Sigma).
Site-directed mutagenesis of the nisin A ‘hinge’ region
The creation of targeted changes was also facilitated using a
PCR-based approach, using oligonucleotides (Table 2) and a
suitable pDF05 based template (one which most closely resembles
the desired change). Amplification was through a 50 ml PCR
reaction containing 0.02 U/ ml KOD Hot-Start Polymerase
(Novagen), 1.5 mM MgSO4, 0.2 mM of each dNTP, 0.3 mM of
both oligonucleotides and approximately 10 ng of template.
Cycling conditions were as described above. Engineered plasmids
were introduced into L. lactis NZ9800nnisA via E. coli Top10 as
described above.
Deferred antagonism assays
Deferred antagonism agar-based assays were employed to assess
the bioactivity of nisin derivative-producing strains [17]. Briefly,
the L. lactis producers were ‘spotted’ (approximately 3 ml) onto
GM17 agar and incubated for 16 hours at 30uC. In the case of M.
smegmatis, the L. lactis producers were incubated for 40 hours.
Growth media (0.75% agar) appropriate for growth of the
individual target was seeded (0.5%) and poured over the L. lactis
producers followed by further incubation at conditions suitable for
the indicator. Enhancement in bioactivity was indicated by
increased zone of inhibition relative to that generated by the wild
type producer.
Figure 1. A - Nisin A mature peptide, B - AAA Producer (Deferred Antagonism Assay). The structure of the mature nisin A peptide and the
zone of inhibition exhibited by the nisin A derivative, AAA. Panel A depicts the amino acid changes that produce the AAA derivative in the nisin
‘hinge’ region. The modified amino acids dehydroalanine and dehydrobutyrine are denoted as Dha and Dhb respectively with the five (b-
methyl)lanthionine rings labelled A to E. Panel B depicts the zones of inhibition produced by L. lactis NZ9800 pDF05(left) and AAA ‘hinge’ variant
(right) against L. lactis HP.
doi:10.1371/journal.pone.0079563.g001
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Agar well diffusion assays
50 ml volumes of purified peptide were added to wells bored in
the appropriate agar-containing media (1.5% agar, 0.75% for M.
smegmatis) seeded with 0.5% of a 16 hour culture (40 hour culture
for M. smegmatis) of the indicator of interest. Plates were incubated
for 16 hours (40 hours for M. smegmatis) and bioactivity assessed on
the basis of the size of the zone of inhibition.
Identification of Nisin A derivatives
Colony mass spectrometric analysis was carried out on colonies
exhibiting enhanced bioactivity using an Axima CFR plus MALDI
TOF mass spectrometer (Shimadzu Biotech, Manchester, UK)
and analyzed in positive-ion reflectron mode as previously
described [8]. The changes to the nisA genes within the
corresponding pDF05 derivatives were established through DNA
sequencing (MWG, Biotech, Germany). The sequences for AAA,
AAK, NAI, SAA and SLS were deposited in GenBank under the
accession numbers KF664587, KF664588, KF664589, KF664590
and KF664591 respectively.
Purification of nisin and derivatives thereof
2 litres of Tryptone Yeast (TY) broth were incubated for
20 hours with 20 ml of an overnight culture of producing strain.
This culture was centrifuged for 20 minutes @ 8630g. The
supernatant was decanted and passed through 60 g of pre
equilibrated Amberlite XAD16 beads (Sigma-Aldrich). The beads
were washed with 500 ml 30% ethanol and eluted with 500 ml
70% isopropanol (IPA) (Fisher) 0.1% trifluoroacetic acid (TFA)
(Sigma-Aldrich). Concomitantly, the cell pellets were resuspended
in 300 ml of 70% IPA 0.1%TFA and stirred at room temperature
for 3 hours followed by centrifugation. This cell supernatant was
combined with that referred to above and concentrated through
rotary-evaporation (Buchi, Switzerland) to approximately 250 ml.
After the pH was adjusted to 4.5 further concentration was
achieved through the use of a Phenomenex SPE C-18 column to a
final volume of 60 ml. 7 ml of this sample was concentrated,
through rotary evaporation, to 2 ml and purified through HPLC
using a Phenomenex C12 Reverse-Phase (RP) HPLC column
(Jupiter 4 m proteo 90 A˚, 250 X 10.0 mm, 4 mm). To facilitate this,
a gradient of 30–50% acetonitrile (Fisher) containing 0.1% TFA
was developed. The relevant fractions were collected and pooled,
Table 1. Plasmids & strains used in used in this study.
Plasmid/Strains Characteristic Reference/Source
pDF05 pCI372 with nisA [8]
pDF05 AAK pDF05 with N20A/M21A substitution in nisA This study
pDF05 AAA pDF05 AAK with K22A substitution in nisA AAK This study
L. lactis NZ9800 L. lactis NZ9700 DnisA [34]
L. lactis NZ9800 pDF05 Wild type nisin A producer [8]
E. coli Top10 Intermediate cloning host Invitrogen
M. smegmatis MC2155 Model microorganism for slow-growing mycobacteria species ATCC
S. agalactiae ATCC 13813 Indicator strain ATCC
L. lactis ssp. cremoris HP Indicator strain UCC Culture Collection
S. aureus RF122 Bovine mastitis-causing isolate [35]
doi:10.1371/journal.pone.0079563.t001
Table 2. Oligonucleotides used in this study.
Oligonucleotide Sequence
NisAXXXHingeFor 5’- PHO TGATGGGTTGTNNKNNKNNKACAGCAACTTGTCATTGTAGT -3’
NisAXXXHingeRev 5’- CAAGTTGCTGTMNNMNNMNNACAACCCATCAGAGCTCCTGT -3’
pCI372Rev 5’- ACCTCTCGGTTATGAGTTAG -3’
For Primer (AAA) 5’- GTTGTGCTGCGGCAACAGCAACTTGTCATTGTAGTATTCAC -3’
Rev Primer (AAA) 5’- CAAGTTGCTGTTGCCGCAGCACAACCCATCAGAGCTCCTGT -3’
AAA Check Primer For 5’- CTGATGGCTTGTGCTGCGGCA -3’
SAA HC For 5’- TGATGGGTTGTTCAGCGGCTACAGCAACTTGTCATTGTAGT -3’
SAA HC Rev 5’- GCTGTAGCCGCTGAACAACCCATCAGAGCTCCTGTTTTACA -3’
SAA Forward SLT Codon 5’- TGATGGGTTGTTCGGCGGCTACAGCAACTTGTCATTGTAGT -3’
SAA Reverse SLT Codon 5’- GCTGTAGCCGCCGAACAACCCATCAGAGCTCCTGTTTTACA -3’
GGG Forward Primer 5’ GATGGGTTGTGGAGGTGGAACAGCAACTTGTCATTGTAGTA ‘3
GGG Reverse Primer 5’ AGTTGCTGTTCCACCTCCACAACCCATCAGAGCTCCTGTTT ‘3
GGG Check Primer 5’ TCTGATGGGTTGTGGAGGTGGA ‘3
PHO – 5’- Phosphate modification. Emboldened – Degenerate codons, emboldened & underlined – locations for site-directed mutagenesis.
doi:10.1371/journal.pone.0079563.t002
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subjected to rotary-evaporation to remove acetonitrile and freeze-
dried (LABCONCO). The purified peptides were subjected to
MALDI-ToF Mass Spectrometric analysis to confirm their purity
before use.
Minimum Inhibitory Concentration (MIC) Assays
Minimum inhibitory concentration assays were carried out in
triplicate using 96-well plates (Sarstedt) pretreated with bovine
serum albumin (BSA) as previously described [26]. Wild type nisin
and nisin derivatives were adjusted to a 500 nM (when using L.
lactis as a target) or 7.5 mM (all other indicators) starting
concentration and 2-fold serial dilutions of each peptide were
carried out. An overnight of the target strain was subcultured and
incubated to an OD600 nm of 0.5 before being diluted to give a
final inoculum of 105cfu/ml in 200ml. The plates were incubated
at an appropriate temperature and inspected after 16 hours. The
MIC was determined as the lowest concentration at which no
growth was visible.
Results
Creation of a bank of producers of randomised hinge
derivatives
In order to fully exploit the potential of the nisin ‘hinge’ region
(N20-M21-K22) to generate enhanced derivatives, it was decided
to undertake a complete randomisation of this area. Using NNK
scanning of the nisin A structural gene (nisA), a large bank of L.
lactis NZ9800 pCI372nisA (pDF05) hinge variants were produced.
In order to obtain full coverage with a 95% confidence limit using
NNK scanning on three positions, a bank of 341,601 variants
would have to be screened [27]. Creating and screening a bank of
this size against four indicators would not have been feasible and
thus a more practical bank of 12,000 variants was produced in
order to increase the likelihood of finding interesting candidates in
a short/medium time frame.
Identification of nisin derivative producers with
enhanced bioactivity
The bank of producers of randomised hinge derivatives was
screened using deferred antagonism agar diffusion assays to
identify producers that display enhanced bioactivity. The term
bioactivity, as used here and elsewhere [8,17,19], reflects the
overall activity of producer strains and does not discriminate
between effects due to increased/decreased specific activity,
altered peptide production levels, or effects on other physico-
chemical properties such as diffusion in agar. Enhanced bioactivity
was characterised by zones of clearing greater than that generated
by the corresponding nisin A producing control against Lactococcus
lactis HP, Streptococcus agalactiae ATCC 13813, Mycobacterium
smegmatis MC2155 or Staphylococcus aureus RF122. From this screen
63 potentially enhanced producers were selected for further
investigation and, after DNA sequencing, it was established that
these corresponded to 23 unique mutants (Table 3).These 23
derivatives contained hinge regions consisting of combinations of
12 distinct amino acids (Table 4), none of which were aromatic or
negatively charged in nature. Of these 12, alanine was most
common (22%), followed by serine (16%) and glutamine (12%).
To exclude that a bias or over-presentation of specific residues had
occurred, and to insure the overall randomisation of the bank, 20
clones were chosen randomly and their hinge region was
sequenced. The results are presented in Table 5 and establish
that alanine and serine are not considerably over-represented
within the bank. From the agar diffusion assays it was apparent
that three producers consistently produced large zones of
inhibition and these were selected for further investigation. DNA
sequencing and mass spectrometric analysis revealed that the
derivatives produced by these strains contained hinge regions
consisting of AAK, SLS and NAI (Table 6). Assays with four target
microorganisms established that the producer of the AAK-
containing derivative exhibited enhanced bioactivity against L.
lactis HP, S. aureus RF122 and M. smegmatis MC2155, the producer
of the SLS-containing derivative exhibited enhanced bioactivity
against L. lactis HP and M. smegmatis MC2155 and the producer of
the NAI-containing derivative exhibited enhanced bioactivity
against L. lactis HP, S. agalactiae ATCC 13813 and M. smegmatis
MC2155. This enhancement could potentially be as a result of
enhanced production, enhanced specific activity or some other
enhancement with respect to the attributes of the peptide. To
investigate these various possibilities, the three peptides produced
by these strains (and wild type nisin A) were purified through
HPLC and broth-based specific activity and agar diffusion assays
were performed (Table 6). Against L. lactis HP, all three
bioengineered peptides displayed enhanced activity, relative to
equal concentrations of nisin A, when assessed through agar
diffusion assays. However, this was not due to enhanced specific
activity as broth-based MIC assays revealed that the activity of the
NAI-containing peptide was equal, and those of the AAK- and
SLS-containing peptides were reduced, relative to that of nisin A
against this target (Table 6). All of the nisin derivatives displayed
specific activity in broth which was reduced relative that of the
wild type peptide against S. aureus RF122, yet the AAK- and NAI-
containing peptides exhibited enhanced activity when assessed
through agar diffusion assays, with the enhanced activity of the
AAK-containing peptide being most significant (Table 6). When
tested against S. agalactiae ATCC 13813, the NAI-containing
peptide displayed significantly enhanced activity against this target
in agar diffusion assays and in broth based specific activity assays.
Regardless of assay, neither the AAK- nor the SLS-containing
peptides exhibited enhanced activity against S. agalactiae ATCC
13813 (Table 6). M. smegmatis MC2155 was also included as an
indicator as M. smegmatis is frequently used as a model
microorganism/substitute for slow-growing, pathogenic mycobac-
teria. The AAK-containing peptide and the SLS-containing
peptides both showed significant enhanced activity against this
target in agar diffusion assays (Table 6), but the aggregative nature
of MC2155 in broth precluded the generation of consistent MIC
data from broth-based studies.
Rational design of nisin derivatives with enhanced
bioactivity
The amino acid composition of nisin hinges within strains
exhibiting enhanced bioactivity revealed some trends. All
‘improved’ hinge regions had a mass less than that of the wild
type, alanines were frequently identified at each position and, on a
number of occasions, multiple alanines were present. Based on
these observations, it was postulated that a nisin derivative with a
hinge consisting of AAA could potentially display enhanced
properties. The presence of a serine, particularly at position 20, in
the nisin hinge of other strains displaying enhanced bioactivity has
also been noted, including hinges consisting of SMT and SLS from
this study and SVA from Rouse et al. [17]. On the basis of this
observation, a nisin derivative containing a SAA hinge was also
created. To further test the theory that nisin derivatives with a
hinge consisting of small amino acids may exhibit enhanced
features, site-directed mutagenesis was also used to create a hinge
derivative consisting of glycine residues only. In this last case, the
producer of the GGG-containing hinge did not exhibit antimi-
Random and Rational Engineering of the Nisin Hinge
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crobial activity. It would thus seem that a lack of chirality within
the hinge is a negative feature.
In contrast, the respective producers of the AAA- and SAA-
containing peptides displayed enhanced bioactivity against each of
the four strains tested and again were purified for specific activity
assays (Table 6). Both the AAA- and SAA-containing peptides
showed significantly enhanced specific activity relative to nisin A
against all four indicators in agar diffusion assays. In each case, this
enhancement was more significant in the case of the AAA-
containing peptide. In contrast, in broth based specific activity
assays the bioengineered peptides exhibited activity that was equal
or reduced relative to that of the wild type peptide, with the
exception that the AAA-containing peptide showed a two-fold
improvement relative to the natural peptide against S. agalactiae
ATCC 13813. Thus, while in many cases it would appear that
enhanced bioactivity is attributable to enhanced diffusion through
complex media, a phenomenon previously reported by Rouse et
al. [17], this result establishes that antimicrobial potency can also
be a contributory factor with respect to some targets.
Discussion
In this study a large bank of derivatives of the lantibiotic nisin
was generated in which all three hinge residues were simulta-
neously randomised. To facilitate the relatively rapid screening of
such a large number of derivative-producing strains, the deferred
antagonism assay was employed. This approach allows for the
identification of variants with enhanced bioactivity and can be
supported by further assays to determine if this enhanced
bioactivity is attributable to enhanced specific activity [15,25]
production and/or solubility/diffusion [17]. Regardless of the
specific underlying basis for the enhanced bioactivity of a
Table 3. Nisin A ‘hinge’ variants with enhanced bioactivity
identified through the initial screen.
Variant Molecular Mass Variant Molecular Mass
HVS 3304 AIT 3266
MAQ 3311 QVQ 3336
ASS 3226 SMT 3300
PVN 3291 HSQ 3332
ASV 3238 HAA 3260
HLA 3301 SIN 3294
NAI 3279 PQK 3334
ANP 3263 AQV 3278
SLS 3268 HSQ 3332
AAI 3236 PNA 3262
AAK 3250 NQV 3321
HLS 3308
The three letter code corresponds to the amino acids located at each of the
three ‘hinge’ sites.
doi:10.1371/journal.pone.0079563.t003
Table 4. Frequency with which amino acids are located at each hinge site among the derivatives presented in Table 3.
Position 20 (% frequency) Position 21 (% frequency) Position 22 (% frequency)
Alanine 7 (30.4) Alanine 5 (21.7) Serine 4 (17.4)
Histidine 6 (26.1) Serine 4 (17.4) Glutamine 4 (17.4)
Proline 3 (13.0) Valine 3 (13.0) Alanine 3 (13.0)
Serine 3 (13.0) Leucine 3 (13.0) Valine 3 (13.0)
Asparagine 2 (8.7) Glutamine 3 (13.0) Isoleucine 2 (8.7)
Glutamine 1 (4.3) Asparagine 2 (8.7) Asparagine 2 (8.7)
Methionine 1 (4.3) Isoleucine 2 (8.7) Lysine 2 (8.7)
Methionine 1 (4.3) Threonine 2 (8.7)
Proline 1 (4.3)
doi:10.1371/journal.pone.0079563.t004
Table 5. Actual and expected frequencies of hinge amino
acids from randomly selected representatives of the hinge
mutant bank.
Amino Acid Residue
Actual
Frequency (%)
Expected
Frequency (%)
Serine 8.33 9.38
Alanine 6.67 6.25
Asparagine 6.67 3.13
Lysine 6.67 3.13
Tyrosine 6.67 3.13
Arginine 5.00 9.38
Glutamine 5.00 3.13
Glycine 5.00 6.25
Histodine 5.00 3.13
Isoleucine 5.00 3.13
Methionine 5.00 3.13
Stop 5.00 3.13
Valine 5.00 6.25
Aspartic Acid 3.33 3.13
Cytosine 3.33 3.13
Glutamic Acid 3.33 3.13
Leucine 3.33 9.38
Proline 3.33 6.25
Threonine 3.33 6.25
Trytophan 3.33 3.13
Phenylalanine 1.67 3.13
doi:10.1371/journal.pone.0079563.t005
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particular derivative, any enhanced feature has the potential to be
exploited in food or medicine. This is especially true when one
considers the number of applications which are available to
lantibiotics, and nisin in particular [1].
Preliminary screening of this bank resulted in the identification
of 23 derivative producers with enhanced bioactivity. Of these 23,
producers of nisin derivatives containing SLS, AAK or NAI within
the hinge region were brought forward for further characterisa-
tion. In the case of the SLS-containing example, the selection of a
strain producing nisin with a serine (S) at positions 20 and 22 was
consistent with observations made by Field et al. [8] and Rouse et
al. [17], who previously established that the introduction of this
hydrophilic amino acid at position 22 and 20 can result in
enhanced bioactivity. Field and co-workers have also previously
noted that the introduction of a leucine (L) at position 21, in
several instances, lead to relatively high levels of activity. With
respect to the NAI-containing derivative, nisin A naturally
contains an asparagine (N) at position 20, the benefits of
incorporating alanines will be discussed in greater depth below
and, although there is no precedent for an enhanced derivative
containing an isoleucine (I) at position 22, its introduction at the
other two hinge positions has had varying effects on bioactivity [8].
The introduction of alanines in the AAK-containing peptide will
be discussed below.
Although this is not the first study which has fully randomised
the nisin ‘hinge’ region, it is the first to do so in the context of the
full length nisin peptide. Previously, Plat and co-workers [28]
randomised all three positions in a truncated form of nisin, i.e.
nisin-(1–22), and found when they analysed 16 of the active
derivatives that the size of the zone was directly, for the most part,
proportional to the amount of the prepeptide produced. However,
in that instance the derivatives that exhibited the largest zones of
activity both contained the aromatic amino acid tryptophan (W);
AWR and WRA. In contrast, in this study none of the peptides
produced by the ‘hinge’ mutants that displayed enhanced
bioactivity contained aromatic amino acids. The differences
between the composition of the hinges in enhanced peptides from
these respective studies suggest that the hinge is performing a
different role in the truncated, relative to the intact, peptide and
that in the latter instance the impact on the hinge residues on the
C terminal domain is critical. Despite these differences, it is
apparent that there is a consistent absence of negatively charged
amino acids from within the hinge of all peptides and strains
exhibiting enhanced bioactivity. This is also consistent with the
previous studies of Field et al. [8] and Yuan et al. [18]
Well diffusion assays using purified forms of the SLS-, AAK-
and NAI-containing peptides established that enhanced bioactivity
was attributable to an enhanced diffusion in agar in a manner
Table 6. Deferred Antagonism and Specific Activity Results.
Deferred Antagonism 100 mg L21 Agar Diffusion MIC
Zone
Area (mm2) p-value
Relative
to WT (%)
Zone
Area (mm2) p-value
Relative
to WT (%)
Specific Activity
as % of WT
L. lactis HP WT 299.5867.04 267.6969.21
AAA 492.83640.27 0.012 164.51 416.00617.99 0.001 155.41 100
AAK 408.89618.72 0.005 136.49 320.08614.20 0.009 119.57 50
SAA 483.14633.89 0.009 161.28 344.76618.50 0.008 138.71 50
SLS 370.75628.28 0.042 123.76 321.93622.43 0.038 120.26 25
NAI 439.52647.88 0.034 146.71 371.32619.60 0.004 128.79 100
S. aureus RF122 WT 138.3163.36 99.34612.33
AAA 292.24611.46 0.001 211.29 155.7763.30 0.011 156.81 25
AAK 292.44610.36 0.001 211.43 178.23613.39 0.002 179.42 50
SAA 236.28613.53 0.004 170.83 130.6064.46 0.036 131.47 25
SLS 153.9367.15 0.045 111.29 98.82610.14 0.957 99.47 ,6
NAI 16.3.23610.95 0.049 118.02 129.75611.36 0.035 130.61 25
S. agalactiae ATCC 13813 WT 226.5562.96 246.3162.74
AAA 401.32615.62 0.002 177.14 305.5862.39 0.000 124.06 200
AAK 232.00621.58 0.706 102.41 234.5564.23 0.021 95.23 50
SAA 407.98618.452 0.003 180.08 301.6268.18 0.004 122.46 100
SLS 209.45617.11 0.223 92.45 226.0564.10 0.003 91.78 25
NAI 318.8167.915 0.034 140.72 291.5268.46 0.007 118.36 200
M. smegmatis MC2155 WT 51.31610.08 67.7964.308
AAA 277.65660.42 0.02 541.09 149.2464.776 0.000 220.15 ND
AAK 199.47632.36 0.009 388.73 105.7366.930 0.003 155.96 ND
SAA 303.85659.93 0.016 592.15 101.19611.510 0.026 149.27 ND
SLS 230.31620.31 0.001 448.84 119.5668.59 0.003 176.36 ND
NAI 270.04658.30 0.02 526.26 78.5068.16 0.137 115.8 ND
The zone of inhibition is expressed as the area of the zone of inhibition minus the area of the ‘spot’ in mm2. MIC: Minimum Inhibitory Concentration. ND: Not
Determined.
doi:10.1371/journal.pone.0079563.t006
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similar to that previously reported by Rouse et al. [17]. This trait
was previously noted as being a valuable one in that such a peptide
performed better than wild type nisin A with respect to controlling
Listeria monocytogenes in a food system. The identity of these, and
other, changes that occurred in the hinge region of peptides
associated with enhanced bioactivity in the preliminary screening
also provided a further insight into the flexibility of the hinge and
revealed distinct patterns (Tables 3 and 4). The frequency with
which alanine appears was particularly notable. Among the strains
that exhibited enhanced bioactivity, alanine was the amino acid
that was most frequently located at positions 20 (30%) and 21
(22%) and was also frequently identified at position 22 (13%). It
was also noted that a pair of alanines was located in the hinge
region of peptides from three strains exhibiting enhanced
bioactivity. The AAK-containing peptide is a perfect example of
this pattern. The third residue, lysine, is conserved across all
natural variants of nisin; nisin A [29], nisin Z [30], nisin Q [31],
nisin F [32], nisin U and U2 [33] and most recently nisin P [34].
The enhanced bioactivity of the corresponding strain and the
specific activity in agar of the corresponding peptide was
particularly apparent against S. aureus RF122 (Table 6). Despite
the conserved nature of this lysine, this study and others [8,17]
have demonstrated that this residue can be changed. On the basis
of these observations it was decided to bioengineer a strain to
produce a peptide in which the ‘hinge’ would consist wholly of
alanines. The fact that these changes enhanced the bioactivity of
the associated strain means that this is the first instance upon
which a characteristic of nisin has been enhanced through rational
design. The additional hinge derivative to result from rational
design contained a hinge consisting of SAA. The creation of this
peptide was targeted due to the previous observation that
enhanced bioactivity was evident in strains that produced peptides
with a serine at position 20 of the nisin peptide, including SMT,
SLS and SVA [17]. The bioactivity of the resultant strain (Table 6)
was also greater than that of nisin wild type producer against all
indicators tested. The fact that the newly introduced serine
remained unmodified is in agreement with observations made
previously by Lubelski [35], where it was suggested that serines in
positions immediately preceding lanthionine bridges remain
unmodified. The fact that the addition of small chiral amino
acids to the hinge resulted in an increase in bioactivity may be
attributable to an increase in ‘hinge’ flexibility. In contrast, the
production of the achiral glycine ‘hinge’ may confer a structurally
weak hyper flexible ‘hinge’ lacking in any distinguishable
conformity through mis-folding. It should also be noted that,
while we focused on the observation that alanine and serine were
frequently identified across all hinge residues in strains with
enhanced bioactivity, there may be merit in designing residues
whereby the amino acid at each respective location is optimised.
Indeed, the positively charged histidine was found very frequently
at position 19 in these strains while, at position 20, the
hydrophobic residues valine, leucine and isoleucine are very
prominent. The identity of the residues located at position 22 was
more variable.
Ultimately, the ‘hinge’ region of nisin has again been established
to be a worthy target with respect to bioengineering to enhance
bioactivity. The benefits of incorporating small chiral amino acids
were particularly apparent leading to, for the first time, the
rational design of nisin ‘hinge’ derivatives with enhanced
properties.
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